Search Results - "Ktorza, N."

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients by Faycal, A., Ndoadoumgue, A.L., Sellem, B., Blanc, C., Dudoit, Y., Schneider, L., Tubiana, R., Valantin, M.-A., Seang, S., Palich, R., Bleibtreu, A., Monsel, G., Godefroy, N., Itani, O., Paccoud, O., Pourcher, V., Caumes, E., Ktorza, N., Chermak, A., Abdi, B., Assoumou, L., Katlama, C.

“…•The clinical presentation of patients with mild COVID-19 varies with age and gender.•Median time to recovery from mild COVID-19 was 27 days.•The probability…”
Get full text

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy by Bossi, P, Peytavin, G, Ait‐Mohand, H, Delaugerre, C, Ktorza, N, Paris, L, Bonmarchand, M, Cacace, R, David, D‐J, Simon, A, Lamotte, C, Marcelin, A‐G, Calvez, V, Bricaire, F, Costagliola, D, Katlama, C

“…Objectives To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy…”
Get full text

Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study by Schneider, L, Ktorza, N, Fourati, S, Assoumou, L, Courbon, E, Caby, F, Blanc, C, Tindel, M, Agher, R, Marcelin, A G, Calvez, V, Peytavin, G, Katlama, C

“…Etravirine (ETR) is recommended as twice-daily dosing in pretreated patients. There are no data regarding the use of ETR once daily in HIV-experienced patients…”
Get more information

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies by Todesco, Eve, Sayon, Sophie, Fourati, Slim, Tubiana, Roland, Simon, Anne, Ktorza, Nadine, Schneider, Luminita, Peytavin, Gilles, Malet, Isabelle, Van den Eede, Peter, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Genevieve, Wirden, Marc

“…There are today HIV-infected patients in therapeutic impasses because of highly multidrug-resistant (HMDR) viruses. We studied the distribution of resistance…”
Get full text

CP-142 Antiretroviral therapy optimisation in multitreated hiv patients: clinical and pharmacoeconomic approach in the ecovir study by Durand, L, Valantin, MA, Ktorza, N, Lenclume, L, Peytavin, G, Wirden, M, Costagliola, D, Assoumou, L, Katlama, C, Patrick, T

“…BackgroundSome patients infected with multiresistant HIV receive lifelong antiretroviral (ARV) treatments. Long term drug effects on the patient and economic…”
Get full text

Pitfalls of HIV genotypic tropism testing after treatment interruption by Wirden, Marc, Soulié, Cathia, Fourati, Slim, Valantin, Marc Antoine, Simon, Anne, Ktorza, Nadine, Tubiana, Roland, Bonmarchand, Manuela, Schneider, Luminita, Calvez, Vincent, Katlama, Christine, Marcelin, Anne-Genevieve

“…The genotypic method is reliable enough for the determination of tropism and largely preferred in Europe. However, careful interpretation is essential when…”
Get full text

Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients by MARCELIN, Anne-Geneviève, LAMOTTE, Claire, BRICAIRE, Francois, COSTAGLIOLA, Dominique, KATLAMA, Christine, PEYTAVIN, Gilles, CALVEZ, Vincent, DELAUGERRE, Constance, KTORZA, Nadine, HOCINE AIT MOHAND, CACACE, Raquel, BONMARCHAND, Manuela, WIRDEN, Marc, SIMON, Anne, BOSSI, Philippe

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients by Ghosn, Jade, Wirden, Marc, Ktorza, Nadine, Peytavin, Gilles, Aït-Mohand, Hocine, Schneider, Luminita, Dominguez, Stéphanie, Bricaire, François, Calvez, Vincent, Costagliola, Dominique, Katlama, Christine

“…To evaluate the potential benefits of a tailored antiretroviral treatment interruption with duration based on the observed reversion of resistance mutations…”
Get full text

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent hiv viraemia under T-20 by MARCELIN, Anne-Geneviève, REYNES, Jacques, CALVEZ, Vincent, YERLY, Sabine, KTORZA, Nadine, SEGONDY, Michel, PIOT, Jean-Claude, DELFRAISSY, Jean-Francois, KAISER, Laurent, PERRIN, Luc, KATLAMA, Christine

“…We analysed the genetic changes in gp41 in a population of 30 heavily pretreated HIV-1-infected patients failing on a T-20-containing salvage therapy. This…”
Get full text

Description clinique et diagnostique sérologique des patients présentant des symptômes persistants après suspicion d’infection à SARS-COV-2 by Seang, S., Ktorza, N., Monsel, G., Abdi, B., Marcelin, A., Valantin, M., Pourcher, V., Caumes, E., Katlama, C., Tubiana, R.

Get full text

Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir by Canestri, A, Blanc, C, Wirden, M, Peytavin, G, Ktorza, N, Katlama, C

Get full text

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy by Wirden, Marc, Delaugerre, Constance, Marcelin, Anne Genevieve, Ktorza, Nadine, Ait Mohand, Hocine, Dominguez, Stephanie, Schneider, Luminita, Ghosn, Jade, Pauchard, Michele, Costagliola, Dominique, Katlama, Christine, Calvez, Vincent

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients by Marcelin, Anne-Geneviève, Affolabi, Dissou, Lamotte, Claire, Mohand, Hocine Ait, Delaugerre, Constance, Wirden, Marc, Voujon, Delphine, Bossi, Philippe, Ktorza, Nadine, Bricaire, François, Costagliola, Dominique, Katlama, Christine, Peytavin, Gilles, Calvez, Vincent

“…Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI‐experienced HIV‐infected patients. Several genotypic resistance…”
Get full text

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20 by Marcelin, A-G, Reynes, J, Yerly, S, Ktorza, N, Segondy, M, Piot, J-C, Delfraissy, J-F, Kaiser, L, Perrin, L, Katlama, C, Calvez, V

“…We analysed the genetic changes in gp41 in a population of 30 heavily pretreated HIV-1-infected patients failing on a T-20-containing salvage therapy. This…”
Get full text

Description clinique et diagnostique sérologique des patients présentant des symptômes persistants après suspicion d’infection à SARS-COV-2 by Seang, S., Ktorza, N., Monsel, G., Abdi, B., Marcelin, A., Valantin, M., Pourcher, V., Caumes, E., Katlama, C., Tubiana, R.

“…La persistance d’une symptomatologie chez des patients suspects d’une infection à SARS-COV-2 est fréquente y compris chez des patients sans diagnostic…”
Get full text

High-performance liquid chromatographic determination of indalpine, a new non-tricyclic antidepressant, in human plasma: identification and simultaneous measurement of its major plasma metabolite by Jozefczak, C, Ktorza, N, Uzan, A

Get more information